Dublin, March 10, 2021 (GLOBE NEWSWIRE) -- The "Global Healthcare Contract Development & Manufacturing Organization Market (2020-2025) by services Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global Healthcare Contract Development & Manufacturing Organization Market is estimated to be USD 193 Bn in 2020 and is expected to reach USD 286 Bn by 2025, growing at a CAGR of 8.2 %.
Key factors, such as the growing number of new molecular entities have led to a demand for high-end technical expertise. Also, at given times, to expedite the drug manufacturing process, pharma companies are depending on CDMOs for their niche technical expertise to get the product in the market. In addition to it, companies are equally focusing on reducing the capital expenditure involved in manufacturing processes. These factors are prominently driving the growth of the contract development and manufacturing organization (CDMO) market.
However, the serialization issues along with the infringement issues related to intellectual property are likely to restrain the market growth.
1. Moderna, Inc and Recipharm AB, a CDMO have drafted an agreement to support the formulation and fill-finish a part of the Moderna COVID-19 Vaccine supply outside the U.S. - 30th December 2020
2. Siegfried has acquired two pharmaceutical manufacturing sites from Novartis based out of Spain. This is in view towards creating a center of excellence for the sites' current technology portfolio in the Barcelona region.- 29th September 2020
Some of the companies covered in this report are Lonza Group Ltd.; Recipharm AB; Siegfried Holding AG; Covance Inc.; Jabil; Sanmina Corporation; IQVIA Holdings Inc.; and Flex.
Key Topics Covered:
1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.4 Years Considered
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
4 Market Overview
4.2 Market Dynamics
126.96.36.199 Need of a high-level expertise to expedite drug manufacturing process
188.8.131.52 Focus of the pharmaceutical companies towards reducing their operational expenses
184.108.40.206 Increasing complexity with the development of new molecular entities
220.127.116.11 Serialization issues faced by healthcare organizations
18.104.22.168 Issues related to infringement of Intellectual Property (IP) rights
22.214.171.124 Rise in the drug approvals cases
126.96.36.199 Technological Advancements
188.8.131.52 Increasing collaborations and investments by CDMOs
184.108.40.206 Compliance issues while outsourcing
5 Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis
6 Global Healthcare Contract Development & Manufacturing Organization Market, By Service
6.2 Contract Development
220.127.116.11 Bioanalysis and DMPK studies
18.104.22.168 Toxicology Testing
22.214.171.124 Other Preclinical Services
126.96.36.199 Phase I
188.8.131.52 Phase II
184.108.40.206 Phase III
220.127.116.11 Phase IV
6.2.3 Laboratory Services
18.104.22.168 Bioanalytical Services
22.214.171.124 Analytical Services
6.3 Contract Manufacturing
6.3.1 API/Bulk Drugs
6.3.2 Finished Dose Formulations
6.3.3 Medical Device
126.96.36.199 Class I
188.8.131.52 Class II
184.108.40.206 Class III
7 Global Healthcare Contract Development & Manufacturing Organization Market, By Solution Type
8 Competitive Landscape
8.1 IGR Competitive Quadrant
8.2 Market Share Analysis
8.3 Competitive Scenario
8.3.1 Mergers & Acquisitions
8.3.2 Agreement, Collaborations, & Partnerships
8.3.3 New Product Launches & Enhancements
8.3.4 Investments & Fundings
9 Company Profiles
9.1 AbbVie Inc.
9.2 Almac Group Ltd.
9.3 Baxter International, Inc.
9.4 B. Braun Melsungen AG
9.5 Boehringer Ingelheim International GmbH
9.6 Catalent Inc.
9.7 Covance Inc.
9.8 Cambrex Corp. (Permira Funds)
9.9 Hisun Pharmaceuticals Inc.
9.10 Jabil Inc.
9.11 Jubilant Life Sciences Ltd.
9.12 IQVIA Holdings Inc
9.14 Lonza Group Ltd.
9.15 Mikart LLC (Nautic Partners)
9.16 Pfizer Inc.
9.17 Probiogen AG (Minapharm Pharmaceuticals)
9.18 Recipharm AB
9.19 Siegfried Holding AG
9.20 Sanmina Corp.
9.21 Stason Pharmaceuticals, Inc.
9.22 Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/bbc9ba
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900